1ROSALIA R A, ARENAS- RAMIREZ N, BOUCHAUD G, et al. Use of enhanced interleukin-2 forumlations for improved immunotherapy against cancer [ J ]. Curr Opin Chem Biol, 2014,23:39-46.
2CARCELAIN G, AUTRAN B. Immune interventions in HIV in- fection[ J]. Immunol Rev,2013,254( 1 ) :355-371.
3MALEK T R, CASTRO I. Interleukin-2 receptor signaling:at the interface between tolerance and immunity [ J ]. Immunity, 2010,33(2) :153-165.
4SAADOUN D,ROSENZWMG M, JOLY F, et al. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vas- culitis [ J ]. N Engl J Med, 2011,365 ( 22 ) : 2067- 2077.
5KRIEG C, LETOURNEAU S, PANTALEO G, et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells [ J ]. Proc Natl Acad Sci USA ,2010,107 (26) : 11906-11911.
6STAUBER D J, DEBLER E W, HORTON P A, et al. Crystal structure of the IL-2 signaling complex : paradigm for a heterot- rimeric cytokine receptor[J]. Proe Natl Acad Sci USA,2006, 103(8) :2788-2793.
7LIAO W,LIN J X,LEONARD W J. Interleukin-2 at the cross- roads of effector responses, tolerance, and immunotherapy [ J ]. Immunity,2013,38 ( 1 ) : 13-25.
8BOYMAN O, SPRENT J. The role of interleukin-2 during ho- meostasis and activation of the immune system [ J ]. Nat Rev Immunol, 2012,12 ( 3 ) : 180-190.
9MARTINS G A, CIMMINO L, LIAO J,et al. Blimp-1 directly represses I12 and the II2 activator Fos, attenuating T cell pro- liferation and survival [J]. J Exp Med, 2008,205 (9) :1959- 1965.
10GENG X,ZHANG R, YANG G, et al. lnterleukin-2 and auto- immune disease occurrence and therapy [ J ] Eur Rev MedPharmacol Sci ,2012,16 ( 11 ) : 1462-1467.
3Basu S, Golovina T, Mikheeva T, et al. Cutting edge: Foxp3- mediated induction of pim 2 allows human T regulatory cells to preferentially expand in raparnycin. J Immunol, 2008, 180(9): 5794-8.
4Strauss L, Whiteside TL, Knights A, et al. Selective survival of naturally occumng human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol, 2007, 178(1): 320-9.
5Liu G, Bums S, Huang G, et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through AktmTOR. Nat Immunol, 2009, 10(7): 769-77.
6Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1- phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol, 2005, 175 02): 7973-80.
7Wang L, Tao R, Hancock WW. Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol, 2009, 87(3): 195-202.
8Webster KE, Wakers S, Kolhler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med, 2009, 206(4): 751- 60.
9Luo X, Tarbell KV, Yang H, et al. Dendritic ceils with TGF- betal differentiate naive CD4+CD25 T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci USA, 2007, 104(8): 2821-6.
10Mason D, Powrie F. Control of immune pathology by regulatory T cells. Curr Opin Immumd 1998.10 (6): 649-55.
